Atsena Announces Initiation of Dosing in Phase I/II Trial Evaluating ATSN-201
Atsena Receives Rare Pediatric Disease Designation from FDA for ATSN-101
ATSN-101 continues to demonstrate clinically meaningful improvements in vision at the highest dose and is well-tolerated 12 months post-treatmentData accepted for presentation at 47th Annual Macula...
RMAT designation recognizes the potential of ATSN-101 to address unmet medical needs for patients with LCA1 ATSN-101 has demonstrated clinically meaningful improvements in vision at the highest dose...
Atsena Therapeutics has cut staff to funnel more money toward an inherited retinal disease program that just began dosing for a phase 1/2 trial in August.
The LIGHTHOUSE study evaluating the safety and tolerability of investigational gene therapy ATSN-201 is enrolling male patients ages 6-64 with RS1-associated XLRS ATSN-201 leverages novel spreading...
ATSN-201 leverages AAV capsid that spreads laterally beyond subretinal injection site to facilitate safe delivery of RS1 to photoreceptors in the central retina/fovea Initiation of Phase I/II...
Atsena Therapeutics Announces Positive 6-month Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
Atsena Therapeutics Announces Six-Month Data from Phase I/II Clinical Trial of ATSN-101 to be Presented at ARVO 2023 Annual Meeting
Atsena Therapeutics to Present Positive Interim Encore Data from the Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1) at the 46th Annual Macula Society Meeting